Elisabeth Parker

Dr. Parker is a business development professional with over 20 years of experience in R&D and the commercialization of innovative research through licensing and spin-outs.

Dr. Parker joined Macrophage Pharma in July 2017, from a Business Development Executive role at Cancer Research Technology Ltd (CRT), the development and commercialization arm of Cancer Research UK, and served as a non-executive Director of cancer diagnostic company Arquer Ltd and cancer therapeutic company Azeria Therapeutics Ltd.

Prior to joining CRT, Dr. Parker was Head of Research at KS Biomedix, a UK-quoted Biopharmaceutical company developing therapeutic antibodies for cancer and inflammation.

Dr. Parker holds an MSc in Molecular Biology and a Ph.D. from the Medical Faculty, Lund University, Sweden where she elucidated the molecular effects of mutations that arise in coagulation factor V and give rise to venous thrombosis.